The purpose of the present invention is to provide a sepetaprost-containing eye drop having exceptional formulation stability. The present invention relates to an eye drop containing sepetaprost, the eye drop being accommodated in an ethylene-oxide-gas-sterilized eye drop container.
The present invention provides a pharmaceutical preparation comprising an aqueous pharmaceutical composition comprising (R)-ll-[2-[2-[(diethylamino)methyl]-lpiperidinyl]acetyl]-5,ll-dihydro-6H-pyrido[2,3-b][l,4]benzodiazepin-6-one or a salt thereof, wherein the aqueous pharmaceutical composition is stored in a package which blocks a light having a wavelength of from 210 to 380 nm, in which the stability of (R)- 11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3- b] [1,4]benzodiazepin-6-one or the salt thereofin the aqueous pharmaceutical composition is improved.
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Software for the recording, viewing, or analyzing health and
medical information; software applications for mobile
devices for the recording, viewing, or analyzing health and
medical information; web application software for the
recording, viewing, or analyzing health and medical
information. Scientific and technological services, namely, scientific
research, analysis, testing, of medical devices and
medicines in the field of pharmaceuticals and human
healthcare; software as a service [SaaS]. Providing medical information, consultancy and advisory
services relating to eye diseases, eye infections and eye
symptoms; medical services relating to eye diseases, eye
infections and eye symptoms; human healthcare services
relating to eye diseases, eye infections and eye symptoms;
medical and pharmaceutical counseling relating to eye
diseases, eye infections and eye symptoms; treatment of eye
diseases, eye infections and eye symptoms; offering medical
information on diseases and on the treatment thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Ophthalmologic preparations; eye drops; pharmaceutical preparations; veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use; food for babies; plasters; materials for dressings; material for stopping teeth; dental wax; disinfectants; fungicides; herbicides.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Eye drops for the reduction of myopia progression;
collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for the treatment of cataracts; pharmaceutical
preparations for the treatment of glaucoma; pharmaceutical
preparations for the treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for the treatment of pinguecula;
pharmaceutical preparations for the treatment of chalazion;
pharmaceutical preparations for the treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for the treatment of
accommodative asthenopia; eye drops for the treatment of
keratoconjunctival epithelial disorder; antibacterial eye
drops; antiallergic eye drops; pharmaceutical preparations;
dietary supplements for humans; nutritional supplements.
Disclosed herein is an aqueous composition comprising 0.001-0.1% (w/v) atropine or a salt thereof, a water-soluble polymer, and buffer (1), which is at a pH range of 6 or lower, wherein the buffer (1) is at least one selected from the group consisting of a phosphate buffer, an aminocarboxylate buffer, a carbonate buffer, an acetate buffer, a tartrate buffer, a borate buffer, and trometamol.
A61K 47/08 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'oxygène
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
9.
EPINASTINE-CONTAINING AQUEOUS COMPOSITION FOR IMPROVING TISSUE TRANSFERABILITY AND PRESERVATIVE EFFECT
The present invention provides an aqueous composition that improves transferability to eye tissue and a preservative effect, that comprises epinastine or a salt thereof in a concentration of 0.1% (w/v), boric acid and/or a salt thereof, and an isotonizing agent, and that has a pH of 6.0-7.7, wherein the concentration of the boric acid and/or the salt thereof is 150-500 mM in terms of boron concentration.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
Intraocular prostheses [lenses] for surgical implantation;
intraocular lens injector; eye droppers for medical
purposes; glaucoma tube shunt; surgical apparatus and
instruments for use in ophthalmic surgery; medical devices
for non-laser glaucoma surgery; ocular implants and devices;
shunts for use in treating glaucoma; stents for use in
treating glaucoma; ophthalmic cutting instruments for use in
treating glaucoma; shunt and stent applicators for use in
treating glaucoma; vision screening instruments for use in
treating glaucoma; ocular implants and devices for use in
treating glaucoma; ophthalmic medical devices; syringes for
medical purposes; medical apparatus; eye wash cups for
medical purposes; finger guards for medical purposes;
pacifier clips; ice bag pillows for medical purposes;
triangular bandages; supportive bandages; surgical catguts;
feeding cups for medical purposes; dropping pipettes for
medical purposes; medical ice bags; medical ice bag holders;
nursing bottles; contraceptive devices; artificial tympanic
membranes; prosthetic or filling materials, not for dental
use; esthetic massage apparatus for commercial use; electric
massage apparatus for household use; gloves for medical
purposes.
11.
WATER-BASED PHARMACEUTICAL COMPOSITION CONTAINING URSODEOXYCHOLIC ACID OR SALT THEREOF
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
12.
PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF
The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present disclosure provides a pharmaceutical composition containing ursodeoxycholic acid or a salt thereof, trometamol or a salt thereof, and water, the pharmaceutical composition having an osmotic pressure of 50-400 mOsm/L, and the amount of trometamol or a salt thereof contained in the pharmaceutical composition being 0.01-3%(w/v).
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
The purpose of the present invention is to provide a pharmaceutical composition that comprises a specific compound and exhibits a superior preservation efficacy, the specific compound being stable within the pharmaceutical composition, and to provide methods for improving the stability of the specific compound within the pharmaceutical composition and the preservation efficacy of the pharmaceutical composition. The pharmaceutical composition according to the present invention comprises isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate or a salt thereof, and further comprises edetic acid or a salt thereof.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
17.
Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention provides a stable pharmaceutical composition comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof and a method of stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
The purpose of the present invention is to provide: a pharmaceutical composition that comprises the pyridylaminoacetic acid compound of the present invention, said pyridylaminoacetic acid compound being stable within the pharmaceutical composition; and a method for improving the stability of the pydridylaminoacetic acid compound within the pharmaceutical composition. The pharmaceutical composition comprises: (6{[4-(pyrazol-1-yl)benzyl](pyridine-3-ylsulfonyl)aminomethyl}pyridine-2-ylamino)isopropyl acetate or a salt thereof; and polyoxyethylene castor oil. The polyoxyethylene castor oil preferably comprises a polyoxyethylene castor oil selected from the group consisting of polyoxyl 5 castor oil, polyoxyl 9 castor oil, polyoxyl 15 castor oil, polyoxyl 35 castor oil, and polyoxyl 40 castor oil.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present disclosure provides an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a sulfur-containing compound having a specified structure.
The purpose of the present invention is to discover a method for stabilizing a composition for ophthalmic use containing sepetaprost, more specifically, a method that facilitates retention of sepetaprost stability at high temperatures, and further, a method that facilitates the retention of shelf life of this composition for ophthalmic use. The present invention is a composition for ophthalmic use, which contains sepetaprost at a concentration of 0.0001 to 0.003% (w/v) and has a pH within a range from 5 to 8.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention provides a pharmaceutical preparation in which an aqueous pharmaceutical composition, which contains (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof, is housed in a packaging that blocks light rays of 210-380 nm in wavelength. In this pharmaceutical preparation, the stability of (R)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof in the aqueous pharmaceutical composition has been improved.
The present invention provides an effective production method and/or purification method for a high-yield and high-purity (R)-11-[[-[(diethylamino)methyl]-1-piperidinyl]-acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one or a salt thereof, said compound not containing impurities, particularly 11-(2-chloroacetyl)-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepine-6-one.
The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.
The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.
The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
09 - Appareils et instruments scientifiques et électriques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Software for the recording, viewing, or analyzing health and medical information; software applications for mobile devices for the recording, viewing, or analyzing health and medical information. Scientific and technological services, namely, scientific research, analysis, testing, of medical devices and medicines in the field of pharmaceuticals and human healthcare; offering information on diseases and on the treatment thereof. Providing medical information, consultancy and advisory services relating to eye diseases, eye infections and eye symptoms; Medical services relating to eye diseases, eye infections and eye symptoms; human healthcare services relating to eye diseases, eye infections and eye symptoms; medical and pharmaceutical counseling relating to eye diseases, eye infections and eye symptoms.
A method for suppressing obstruction of meibomian gland in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to an eye of the mammalian subject 1 to 2 times per day.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
29.
AGENT FOR TREATING MYOPIA, PREVENTING MYOPIA AND/OR SUPPRESSING MYOPIA PROGRESSION
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (Allemagne)
Inventeur(s)
Inaba, Takaaki
Kato, Masatomo
Abrégé
The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (−)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; pharmaceutical
preparations for treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for treatment of pinguecula;
pharmaceutical preparations for treatment of chalazion;
pharmaceutical preparations for treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for treatment of accommodative
asthenopia; eye drops for treatment of keratoconjunctival
epithelial disorder; antibacterial eye drops; antiallergic
eye drops; pharmaceutical preparations; reagent paper for
medical purposes; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for medical use; capsules for medicines; eyepatches
for medical purposes; ear bandages for medical purposes;
menstruation bandages; menstruation tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton sticks for medical purposes;
diapers; diaper covers; dietary supplements for humans;
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; pharmaceutical
preparations for treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for treatment of pinguecula;
pharmaceutical preparations for treatment of chalazion;
pharmaceutical preparations for treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for treatment of accommodative
asthenopia; eye drops for treatment of keratoconjunctival
epithelial disorder; antibacterial eye drops; antiallergic
eye drops; pharmaceutical preparations; reagent paper for
medical purposes; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for medical use; capsules for medicines; eyepatches
for medical purposes; ear bandages for medical purposes;
menstruation bandages; menstruation tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton sticks for medical purposes;
diapers; diaper covers; dietary supplements for humans;
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals.
32.
SILVER SALT-CONTAINING OPHTHALMIC AQUEOUS COMPOSITION FILLED IN RESIN CONTAINER
The present invention relates to an ophthalmic aqueous composition containing a silver salt, and filled in a container made of a polyester-based resin, or a container made of a polyolefin-based resin excluding polypropylene. Besides, the present invention also relates to an ophthalmic preservative containing a silver salt, and filled in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene, and a method for imparting, to an ophthalmic aqueous composition, preservative efficacy satisfying a criterion of Preservatives-Effectiveness Tests of The Japanese Pharmacopoeia, including adding a silver salt to the ophthalmic aqueous composition, and filling the ophthalmic aqueous composition in a container made of a polyester-based resin or a container made of a polyolefin-based resin excluding polypropylene. The present invention provides a preservative/system widely usable in ophthalmic aqueous compositions regardless of types of active ingredients and additives.
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
33.
SULFUR-CONTAINING COMPOUND USEFUL FOR TREATING OR PREVENTING PRESBYOPIA OR LIKE
The present disclosure provides: a sulfur-containing compound which has a predetermined structure and is useful for treating or preventing eye diseases such as presbyopia and cataracts; and an agent for treating or preventing eye diseases such as presbyopia and cataracts, the agent containing said sulfur-containing compound as an active ingredient.
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p. ex. cromakalim
A61K 31/4155 - 1,2-Diazoles non condensés et contenant d'autres hétérocycles
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
C07D 409/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 413/06 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (Allemagne)
Inventeur(s)
Oki, Kenji
Nagano, Takashi
Asano, Nagayoshi
Fujisawa, Koushi
Abrégé
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (Allemagne)
Inventeur(s)
Oki, Kenji
Nagano, Takashi
Asano, Nagayoshi
Fujisawa, Koushi
Abrégé
A compound useful for preventing or treating dry eye and a medicament for preventing and/or treating dry eye comprising the same which does not substantially impact on the intraocular pressure are provided. The present invention relates to a medicament for preventing and/or treating dry eye, comprising olodaterol or a salt thereof as an active ingredient.
The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop.
The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop.
The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
38.
USE OF VALPROIC ACID FOR REDUCING POST-OPERATIVE SCARRING FOLLOWING A GLAUCOMA SURGERY
The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.
A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
Described is a combination of a prophylactic or therapeutic agent for glaucoma or ocular hypertension, which is useful as a prophylactic or therapeutic agent for glaucoma or ocular hypertension. By combining sepetaprost and a Rho-associated coiled-coil containing protein kinase inhibitor(s), an intraocular pressure lowering action is enhanced as compared with the case where each drug is used alone. As the form of administration, they may be administered concomitantly or may be administered as a combination drug.
A61K 31/335 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine
A61K 31/472 - Isoquinoléines non condensées, p. ex. papavérine
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
An examination system (1000) comprises: a camera (16); a processor (21) for examining the wetness of an eye, on the basis of captured images obtained as a result of the camera (16) imaging the eye, and an estimation model (232) that includes a neural network (2321); and a display (15) that displays the results of the examination executed by the processor (21).
A61B 3/10 - Appareils pour l'examen optique des yeuxAppareils pour l'examen clinique des yeux du type à mesure objective, c.-à-d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Educational services. Providing medical and scientific research information in the
field of pharmaceuticals and clinical trials; hosting of
websites. Medical services; providing medical information; medical
counselling services; provision of pharmaceutical
information.
43.
WATER-BASED PHARMACEUTICAL COMPOSITION CONTAINING URSODEOXYCHOLIC ACID OR SALT THEREOF
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
(1) Educational services in the field of eye care and eye treatment products
(2) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting websites.
(3) Medical services, namely, medical analysis for ophthalmological and eye disease prevention, screening, diagnosis and treatment; Providing medical information in the field of eye care and eye treatment; Medical counselling in the field of eye care and eye treatment; provision of pharmaceutical information.
47.
FORCING AND PRODUCING METHOD FOR LAYERED RETINAL TISSUE INCLUDING PHOTORECEPTOR CELLS
The present invention provides a method for producing a layered retinal tissue including photoreceptor cells from pluripotent stem cells or an aggregate including retinal progenitor cells within a short period.
The present invention provides a pharmaceutical composition for topical administration, which contains epinastine or a salt thereof as an active ingredient at a concentration of 0.05 to 1% (w/w) and which enables long-term retention of the active ingredient concentration in eye tissue even when the dose is a low concentration.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
The present invention provides a pharmaceutical composition for transdermal administration, the pharmaceutical composition being capable of maintaining an effective concentration in eye tissue and maintaining stability for a long time, and containing epinastine or a salt thereof and a sulfur-based antioxidant.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 47/06 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; pharmaceutical
preparations for treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for treatment of pinguecula;
pharmaceutical preparations for treatment of chalazion;
pharmaceutical preparations for treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for treatment of accommodative
asthenopia; eye drops for treatment of keratoconjunctival
epithelial disorder; antibacterial eye drops; antiallergic
eye drops; pharmaceutical preparations; reagent paper for
medical purposes; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for medical use; capsules for medicines; eyepatches
for medical purposes; ear bandages for medical purposes;
menstruation bandages; menstruation tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton sticks for medical purposes;
diapers; diaper covers; dietary supplements for humans;
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for ophthalmological use; Sanitary preparations for medical purposes for the treatment of eye diseases and eye conditions.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; pharmaceutical
preparations for treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for treatment of pinguecula;
pharmaceutical preparations for treatment of chalazion;
pharmaceutical preparations for treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for treatment of accommodative
asthenopia; eye drops for treatment of keratoconjunctival
epithelial disorder; antibacterial eye drops; antiallergic
eye drops; pharmaceutical preparations; reagent paper for
medical purposes; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for medical use; capsules for medicines; eyepatches
for medical purposes; ear bandages for medical purposes;
menstruation bandages; menstruation tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton sticks for medical purposes;
diapers; diaper covers; dietary supplements for humans;
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Breath freshening preparations; soaps and detergents;
dentifrices; cosmetics; make-up powder; toilet water; beauty
serums; eye cream for cosmetic purposes; beauty balm creams;
gel eye patches for cosmetic purposes; gel eye masks;
cosmetic creams; cosmetic oils; eye lotions for cosmetic
purposes; cosmetic rouges; hair care preparations; perfumes;
natural perfumery prepared from vegetables; natural
perfumery prepared from animals; synthetic perfumery;
blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions;
balms for medical purposes; ointments for pharmaceutical
purposes; ophthalmic preparations; pharmaceutical
preparations; reagent paper for medical purposes; oiled
paper for medical purposes; tapes (adhesive -), for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary pads; sanitary panties; absorbent cotton;
adhesive plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton swabs for medical use; dental
materials; diapers; diaper covers; fly catching paper;
mothproofing paper; lacteal flour for babies; dietary
supplements for humans; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals; semen for artificial insemination. Intraocular lenses; intraocular lens injector; eye droppers
for medical purposes; glaucoma tube shunt; ophthalmologic
apparatus and instruments; syringes for medical purposes;
medical apparatus and instruments; cups for eye-washes;
finger guards for medical purposes; pacifier clips; ice bag
pillows for medical purposes; triangular bandages;
supportive bandages; surgical catguts; feeding cups for
medical purposes; dropping pipettes for medical purposes;
teats; ice bags for medical purposes; medical ice bag
holders; baby bottles; nursing bottles; contraceptive
devices; artificial tympanic membranes; prosthetics or
fillings materials, not for dental use; ear plugs for
sleeping; ear plugs for protection against noise; esthetic
massage apparatus for commercial use; electric massage
apparatus for household purposes; gloves for medical
purposes; portable hand-held urinals; bed pans; ear picks;
sanitary masks for medical purposes; parts, fittings and
accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and
services of others through the administration of sales and
promotional incentive schemes involving trading stamps;
business management analysis or business consultancy;
marketing research or analysis; providing information
concerning commercial sales; business management; business
administration services for the processing of sales made on
the internet; promoting the goods and services of others
over the internet; provision of an online marketplace for
buyers and sellers of goods and services; commercial
intermediation services; commercial administration of the
licensing of the goods and services of others;
administration of consumer loyalty programs; website traffic
optimization; presentation of goods on communication media,
for retail purposes; auctioneering; import-export agency
services; publicity material rental; rental of advertising
space; providing commercial information and advice for
consumers in the choice of products and services; retail
services or wholesale services for pharmaceutical,
veterinary and sanitary preparations and medical supplies;
retail services or wholesale services for cosmetics,
toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts,
crafts, sports or general knowledge; teaching; educational
and instruction services; teaching in the field of cosmetics
and medicines; arranging, conducting and organization of
seminars; arranging and conducting of seminars, workshops
[education], congresses, colloquia, distance learning
courses and exhibitions for cultural purposes; providing
electronic publications; providing videos from the internet,
not downloadable; providing digital music from the internet,
not downloadable; providing images from the internet, not
downloadable; entertainment services; entertainment
information; photography. Providing information about beauty; beauty consultancy;
provision of medical information; providing information
relating to ophthalmology services; dietary and nutritional
guidance; providing information relating to dietary and
nutritional guidance; providing information relating to
nursing care; nursing home services; medical equipment
rental; providing information relating to the rental of
medical machines and apparatus; health care.
03 - Produits cosmétiques et préparations de toilette; préparations pour blanchir, nettoyer, polir et abraser.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Breath freshening preparations; soaps and detergents;
dentifrices; cosmetics; make-up powder; toilet water; beauty
serums; eye cream for cosmetic purposes; beauty balm creams;
gel eye patches for cosmetic purposes; gel eye masks;
cosmetic creams; cosmetic oils; eye lotions for cosmetic
purposes; cosmetic rouges; hair care preparations; perfumes;
materials; natural perfumery prepared from vegetables;
natural perfumery prepared from animals; synthetic
perfumery; blended perfumery; incense; false eyelashes. Collyrium; eye drops; medicinal creams; medicated lotions;
balms for medical purposes; ointments for pharmaceutical
purposes; ophthalmic preparations; pharmaceutical
preparations; reagent paper for medical purposes; oiled
paper for medical purposes; tapes (adhesive -), for medical
purposes; drug delivery agents in the form of edible wafers
for wrapping powdered pharmaceuticals; gauze for dressings;
empty capsules for pharmaceuticals; eyepatches for medical
purposes; ear bandages; menstruation bandages; menstruation
tampons; sanitary pads; sanitary panties; absorbent cotton;
adhesive plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton swabs for medical use; dental
materials; diapers; diaper covers; fly catching paper;
mothproofing paper; lacteal flour for babies; dietary
supplements for humans; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals; semen for artificial insemination. Laboratory apparatus and instruments; measuring or testing
machines and instruments; sensors [measurement apparatus],
other than for medical use; telecommunication machines and
apparatus; personal digital assistants; application software
for mobile devices; electronic machines, apparatus and their
parts; computer programs; computers and their peripherals;
computer software applications, downloadable; computer
software, recorded; eyeglasses; downloadable music files;
downloadable image files; downloadable video files;
electronic publications; parts, fittings and accessories for
all the aforementioned goods. Intraocular lenses; intraocular lens injector; eye droppers
for medical purposes; glaucoma tube shunt; ophthalmologic
apparatus and instruments; syringes for medical purposes;
medical apparatus and instruments; cups for eye-washes;
finger guards for medical purposes; pacifier clips; ice bag
pillows for medical purposes; triangular bandages;
supportive bandages; surgical catguts; feeding cups for
medical purposes; dropping pipettes for medical purposes;
teats; ice bags for medical purposes; medical ice bag
holders; baby bottles; nursing bottles; contraceptive
devices; artificial tympanic membranes; prosthetics or
fillings materials, not for dental use; ear plugs for
sleeping; ear plugs for protection against noise; esthetic
massage apparatus for commercial use; electric massage
apparatus for household purposes; gloves for medical
purposes; portable hand-held urinals; bed pans; ear picks;
sanitary masks for medical purposes; parts, fittings and
accessories for all the aforementioned goods. Advertising and publicity services; promoting the goods and
services of others through the administration of sales and
promotional incentive schemes involving trading stamps;
business management analysis or business consultancy;
marketing research or analysis; providing information
concerning commercial sales; business management; business
administration services for the processing of sales made on
the internet; promoting the goods and services of others
over the internet; provision of an online marketplace for
buyers and sellers of goods and services; commercial
intermediation services; commercial administration of the
licensing of the goods and services of others;
administration of consumer loyalty programs; website traffic
optimization; presentation of goods on communication media,
for retail purposes; auctioneering; import-export agency
services; publicity material rental; rental of advertising
space; providing commercial information and advice for
consumers in the choice of products and services; retail
services or wholesale services for pharmaceutical,
veterinary and sanitary preparations and medical supplies;
retail services or wholesale services for cosmetics,
toiletries, dentifrices, soaps and detergents. Educational and instruction services relating to arts,
crafts, sports or general knowledge; teaching; educational
and instruction services; teaching in the field of cosmetics
and medicines; arranging, conducting and organization of
seminars; arranging and conducting of seminars, workshops
[education], congresses, colloquia, distance learning
courses and exhibitions for cultural purposes; providing
electronic publications; providing videos from the internet,
not downloadable; providing digital music from the internet,
not downloadable; providing images from the internet, not
downloadable; entertainment services; entertainment
information; photography. Designing of machines, apparatus, instruments [including
their parts] or systems composed of such machines, apparatus
and instruments; design services; computer programming;
creation, design and maintenance of web sites; creation,
maintenance, and updating of computer software; monitoring
of computer systems by remote access; testing, inspection or
research of pharmaceuticals, cosmetics or foodstuffs;
quality control; rental of computers; providing computer
programs on data networks; rental of web servers; cloud
computing; software as a service [SaaS]; platform as a
service [PaaS]; hosting computer sites [web sites];
electronic data storage. Providing information about beauty; beauty consultancy;
provision of medical information; providing information
relating to ophthalmology services; dietary and nutritional
guidance; providing information relating to dietary and
nutritional guidance; providing information relating to
nursing care; nursing home services; medical equipment
rental; providing information relating to the rental of
medical machines and apparatus; health care.
55.
AQUEOUS OPHTHALMIC SOLUTION CONTAINING ALKYLDIAMINOETHYLGLYCINE OR SALT THEREOF
The problem addressed by the present invention is that of searching for an easy-to-handle diquafosol/preservative combination for preparing a diquafosol ophthalmic solution that does not exhibit a change in formulation, is clear in color, and also has sufficient preservative efficacy. The present invention is an aqueous ophthalmic solution containing diquafosol or a salt thereof as an active ingredient, and containing an alkyldiaminoethylglycine or a salt thereof.
The present invention addresses the problem of searching for an easily handleable combination of diquafosol and an antiseptic agent when producing a clear diquafosol eye drop having sufficient preservation efficacy. The present invention is an aqueous eye drop which contains diquafosol or a salt thereof as an active ingredient and contains polidronium chloride.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
The present invention addresses the problem of exploring an additional combination of diquafosol and a preservative, said combination enabling the preparation of a clear diquafosol ophthalmic solution, while having sufficient preservative efficacy. The present invention provides an aqueous ophthalmic solution which contains diquafosol or a salt thereof as an active ingredient, while also containing polyhexamethylene biguanide or a salt thereof.
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
The present disclosure provides and an agent for treating or preventing an eye disease such as presbyopia, comprising, as an active ingredient, a lipoic acid prodrug having a specified structure.
A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Collyrium; eye drops; ophthalmic pharmaceutical
preparations; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; pharmaceutical
preparations for treatment of ocular hypertension;
ophthalmic ointments, creams, lotions and gels;
pharmaceutical preparations for use in eye injections;
pharmaceutical preparations for treatment of pinguecula;
pharmaceutical preparations for treatment of chalazion;
pharmaceutical preparations for treatment of uveitis;
pharmaceutical preparations for improving focus-adjustment
function declined by accommodative asthenopia;
pharmaceutical preparations for treatment of accommodative
asthenopia; eye drops for treatment of keratoconjunctival
epithelial disorder; antibacterial eye drops; antiallergic
eye drops; pharmaceutical preparations; reagent paper for
medical purposes; oiled paper for medical purposes; adhesive
tapes for medical purposes; drug delivery agents in the form
of edible wafers for wrapping powdered pharmaceuticals;
gauze for medical use; capsules for medicines; eyepatches
for medical purposes; ear bandages for medical purposes;
menstruation bandages; menstruation tampons; sanitary
napkins; sanitary panties; absorbent cotton; adhesive
plasters; bandages for dressings; liquid bandages;
breast-nursing pads; cotton sticks for medical purposes;
diapers; diaper covers; dietary supplements for humans;
nutritional supplements; dietetic beverages adapted for
medical purposes; dietetic foods adapted for medical
purposes; beverages for babies; food for babies; dietary
supplements for animals.
To prove an optical probe that can illuminate an entire desired region at one time, even in a narrow space. An optical probe including: a linear light guide to guide light from a light source device; a planar emitter to be connected to a tip portion of the linear light guide, to emit the light; a reflective surface provided in a part of the planar emitter, to reflect the light having entered the planar emitter; and an emitting surface provided so as to face the reflective surface, to allow the light reflected by the reflective surface to be emitted from a region of the reflective surface.
The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.
The present invention provides: a stable pharmaceutical composition containing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof; and a method for stabilizing (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5, 11-dihydro-6H-pyrido[2, 3-b][1, 4]benzodiazepine-6-one or a salt thereof.
The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
64.
BISPECIFIC BINDING MOLECULES AGAINST VEGF AND ANG2
The present disclosure relates to bispecific binding molecules against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2), including protein sequences, methods for their production, pharmaceutical compositions containing the bispecific binding molecules, and therapeutic and diagnostic uses thereof.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 14/71 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des facteurs de croissanceRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des régulateurs de croissance
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C12N 15/12 - Gènes codant pour des protéines animales
The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, ursodeoxycholic acid or an amide conjugate of ursodeoxycholic acid, or an ester thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/575 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne d'au moins trois atomes de carbone, p. ex. cholane, cholestane, ergostérol, sitostérol
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
66.
Agent containing 4-phenylbutyrate, for preventing or treating presbyopia
The present disclosure provides an agent for treating or preventing eye diseases such as presbyopia, comprising, as an active ingredient, 4-phenylbutyric acid or an ester thereof, or a pharmaceutically acceptable salt thereof.
A61K 31/192 - Acides carboxyliques, p. ex. acide valproïque ayant des groupes aromatiques, p. ex. sulindac, acides 2-aryl-propioniques, acide éthacrynique
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Educational services. Providing medical and scientific research information in the
field of pharmaceuticals and clinical trials; hosting
websites. Medical services; providing medical information; medical
counselling services; provision of pharmaceutical
information.
68.
OPHTHALMIC COMPOSITION CONTAINING DIQUAFOSOL OR SALT THEREOF, VINYL-BASED POLYMER AND CELLULOSE-BASED POLYMER
Provided is an ophthalmic composition comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. Also provided is an agent for prevention or treatment of dry eyes, comprising diquafosol or a salt thereof, a vinyl-based polymer and a cellulose-based polymer. These solution-type aqueous eye drop for treatment of dry eye each comprises diquafosol sodium with a concentration of 3% (w/v), hydroxyethyl cellulose and polyvinylpyrrolidone having a K value of 30, and is characterized in that a single dose of 1 to 2 drops is administered by eye drop three times per day.
A61K 31/7042 - Composés ayant des radicaux saccharide et des hétérocycles
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
Provided is a pharmaceutical preparation for treatment or prevention of glaucoma or ocular hypertension, comprising 0.0003 to 0.01% (w/v) of isopropyl (6-{[4-(pyrazol-1-yl)benzyl](pyridin-3-ylsulfonyl)aminomethyl}pyridin-2-ylamino)acetate, or a salt thereof.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
The purpose of the present invention is to identify a drug formulation for the treatment or prevention of glaucoma or ocular hypertension, wherein the drug formulation exhibits an effect in patients with drug-refractory glaucoma or ocular hypertension. Sepetaprost is expected to exhibit an excellent intraocular pressure-lowering action in patients with otherwise drug-refractory glaucoma or ocular hypertension. The drug formulation according to the present invention containing sepetaprost as an active ingredient is therefore useful as a drug formulation that can treat or prevent glaucoma or ocular hypertension in patients with otherwise drug-refractory glaucoma or ocular hypertension.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (Allemagne)
Inventeur(s)
Inaba, Takaaki
Kato, Masatomo
Abrégé
The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
A drive unit 100 for liquid ejection allows a user to eject a fixed amount of liquid easily and economically without complicating manufacturing tasks and liquid replenishment tasks, and is for actuating a pump bottle 10 having a discharge port 13, a storage part 11, and a support base 12, the pump bottle being configured such that when the storage part 11 moves, relative to the support base 12, from a normal state position to an operation position, liquid stored in the storage part 11 is ejected through the discharge port 13. This drive unit for liquid ejection comprises: a unit body 20 that allows installation of the pump bottle 10 with the discharge port 13 exposed to the outside; a pusher 35 which is provided to the unit body 20 such that the pusher can face the pump bottle 10 installed to the unit body 20 and can move along the movement direction of the storage part 11; and a main drive member 31, a driven member 32, and a biasing spring 33 which are for moving, relative to the unit body 20, the pusher 35 between the normal state position and the operation position, such movement driven by an electric motor 40.
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (Allemagne)
Inventeur(s)
Inaba, Takaaki
Kato, Masatomo
Abrégé
The present invention relates to a pharmaceutical composition for treating myopia, preventing myopia and/or suppressing myopia progression, comprising (+)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof as an active ingredient, wherein the pharmaceutical composition is substantially free of (-)-11-[2-[2-[(diethylamino)methyl]-1-piperidinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one or a salt thereof.
The present invention provides an improvement in the strength of the scleral by collagen fiber crosslinking via crosslinking treatment of the sclera at the equatorial region of the eye and/or at the posterior pole such as the fundus of the eye. Also provided is the prevention and/or treatment of eye disease by the same. Provided are: a photosensitizer used in a crosslinking treatment for the sclera at the equatorial region of the eye and/or at the posterior pole of the eye; a kit containing the same; and a method for emitting light for the crosslinking treatment.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61F 9/007 - Procédés ou dispositifs pour la chirurgie de l'œil
A61K 31/525 - Iso-alloxazines, p. ex. riboflavines, vitamine B2
A61K 31/661 - Acides du phosphore ou leurs esters n'ayant pas de liaison P-C, p. ex. fosfosal, dichlorvos, malathion
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 41/17 - Inactivation ou décontamination d'une préparation médicinale avant son administration à un animal ou une personne par lumière ultraviolette [UV] ou infrarouge [IR], rayons X ou rayons gamma
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
The present invention provides a novel VEGF-binding peptide or a compound including a novel VEGF-binding peptide structure. For example, the present invention provides a compound represented by the following formula (I) (where peptide A is represented by the following formula (A), and each of the groups is as defined in the description) or a pharmaceutically acceptable salt thereof.
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p. ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p. ex. PEG, PPG, PEO ou polyglycérol
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A promoting agent for the secretion of a lipid, which contains diquafosol or a salt thereof as an active ingredient, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof as an active ingredient, which is intended to be used for the promotion of the secretion of a lipid, in which the type of the secretion of the lipid is of a holocrine type. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the holocrine-type secretion of a lipid from a meibomian gland cell. An ophthalmic composition containing diquafosol or a salt thereof, which is intended to be used in an in vivo treatment method for promoting the secretion of a lipid from a meibomian gland cell, in which the lipid is at least one component selected from the group consisting of a wax ester, a triglyceride, an omega-hydroxy lipid, cholesterol, a cholesterol ester, total cholesterol, a phospholipid, a fatty acid and a fatty alcohol.
The present disclosure provides an agent for treating or preventing ophthalmopathy such as presbyopia, the agent containing as an active ingredient a sulfur-containing compound having a prescribed structure.
A61P 27/10 - Agents ophtalmiques pour le traitement des troubles d'accommodation, p. ex. myopie
C07C 323/12 - Thiols, sulfures, hydropolysulfures ou polysulfures substitués par des halogènes, des atomes d'oxygène ou d'azote ou par des atomes de soufre ne faisant pas partie de groupes thio contenant des groupes thio et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné ayant les atomes de soufre des groupes thio liés à des atomes de carbone acycliques du squelette carboné le squelette carboné étant acyclique et saturé
C07D 339/04 - Cycles à cinq chaînons comportant les hétéro-atomes en positions 1, 2, p. ex. acide lipoïque
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Educational services. Scientific and technological services; offering scientific information on diseases and on the treatment thereof; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; hosting of websites. Medical services; healthcare services; providing of medical information; medical counselling services; provision of pharmaceutical information.
79.
Agent for treating or preventing glaucoma including a sulfonamide compound and another drug
A preventive or therapeutic agent for glaucoma or ocular hypertension includes a combination of isopropyl (6-{[4-(pyrazol-1-yl)benzyl] (pyridin-3-ylsulfonyl) aminomethyl}pyridin-2-ylamino)acetate with one or more other preventive or therapeutic drugs for glaucoma or ocular hypertension, with the proviso that tafluprost is excluded.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/4178 - 1,3-Diazoles non condensés et contenant d'autres hétérocycles, p. ex. pilocarpine, nitrofurantoïne
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
80.
AQUEOUS COMPOSITION CONTAINING EPINASTINE OR SALT THEREOF
The present invention provides an aqueous composition for enhancing transferability into ocular tissue, the aqueous composition containing epinastine or a salt thereof and a quaternary ammonium compound, wherein the content ratio of the quaternary ammonium compound with respect to the epinastine or salt thereof is 0.1 part by weight or less with respect to 1 part by weight of the content of the epinastine or salt thereof.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 47/16 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention pertains to an ophthalmic aqueous composition containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic aqueous composition. The present invention also pertains to: an ophthalmic preservative containing a silver salt, wherein a polyester resin container or a polyolefin (excluding polypropylene) resin container is filled with the ophthalmic preservative; and a method for imparting storage efficacy that meets the storage efficacy test standards of the Japan Pharmacopoeia to an ophthalmic aqueous composition, wherein the method includes a step for adding a silver salt to the ophthalmic aqueous composition, and a step for filling a polyester resin container or a polyolefin (excluding polypropylene) resin container with the ophthalmic aqueous composition. The present invention provides a preservative/system that can be widely used in ophthalmic aqueous compositions irrespective of types of active ingredients and additives.
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention makes it possible to prepare a rebamipide-containing aqueous suspension that has similar properties to Mucosta® ophthalmic suspension UD2%, without using PVA as an additive, from an aqueous suspension that contains rebamipide or a salt thereof and at least one polymer selected from the group consisting of carmellose sodium, dextran, and polyvinylpyrrolidone.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations for the treatment of cataracts, glaucoma, ocular hypertension, pinguecula, chalazion, uveitis, and eye diseases and conditions; pharmaceutical preparations, namely, collyrium, eye drops, ophthalmic preparations, and ophthalmic ointments for the treatment of eye diseases and conditions; pharmaceutical preparations for use in eye injections for the treatment of eye diseases and conditions
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
86.
DRUG COMPOSITION FOR TREATING NEARSIGHTEDNESS, PREVENTING NEARSIGHTEDNESS, AND/OR MINIMIZING PROGRESSION OF NEARSIGHTEDNESS
The present invention provides a drug composition for treating nearsightedness, preventing nearsightedness, and/or minimizing progression of nearsightedness, including, as an active ingredient, 4-{(3S, 5ar, 6R, 7R, 8aS)-6-[(1E, 3R)-4-(2,5-difluorophenoxy)-3-hydroxy-1-butene-1-yl]-7-hydroxyoctahydro-2H-cyclopenta[b]oxepin-3-yl}butanoic acid, an ester thereof or a salt thereof.
The present invention provides a pharmaceutical composition for treating myopia, preventing myopia, and/or suppressing progression of myopia, the pharmaceutical composition containing omidenepag or an ester thereof, or a salt of these, as an active ingredient.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
The purpose of the present invention is to provide an aqueous suspension composition comprising poorly water-soluble sirolimus or a salt thereof for ophthalmology, in particular, used for topical administration, such as a less invasive eye drop. The present invention is an ophthalmic aqueous suspension composition comprising sirolimus or a salt thereof and a surfactant, wherein the aqueous suspension composition has a pH of 4 to 6.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
The purpose of the present invention is to provide an aqueous suspension composition that contains poorly soluble sirolimus and that is for use in ophthalmology, especially in topical administration of less-invasive eye drops or the like. This aqueous suspension composition is for use in ophthalmology, contains a surfactant and sirolimus or a salt thereof, and has a pH of 4-6.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.
The present invention relates to the use of valproic acid for reducing post-operative scarring following a glaucoma surgery. In one embodiment, the glaucoma surgery is glaucoma filtering surgery, which comprises creating a subconjunctival bleb. In another embodiment, the glaucoma surgery is minimally invasive glaucoma surgery (MIGS), which comprises implanting a glaucoma tube shunt under a subconjunctival space.
A61K 31/19 - Acides carboxyliques, p. ex. acide valproïque
A61P 41/00 - Médicaments utilisés en chirurgie, p. ex. adjuvants chirurgicaux pour la prévention des adhérences ou pour le remplacement de l'humeur vitrée
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
(1) Educational services, namely, conducting virtual and in-person educational events consisting of classes, webinars, workshops and training in the field of medicine.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, conducting virtual and in-person educational events consisting of classes, webinars, workshops and training in the field of ophthalmology
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceuticals, medical and veterinary preparations;
sanitary preparations for medical purposes; dietetic food
and substances adapted for medical or veterinary use; food
for babies; dietary supplements for human being and animals;
plasters, materials for dressings; material for stopping
teeth, dental wax; disinfectants; preparations for
destroying vermin; fungicides, herbicides; eye drops;
collyrium; ophthalmological preparations; pharmaceutical
preparations for treatment of cataracts; pharmaceutical
preparations for treatment of glaucoma; eye drops for
treatment of glaucoma; pharmaceutical preparations for
treatment of ocular hypertension; ophthalmic ointments,
creams, lotions and gels; pharmaceutical preparations for
use in eye injections; pharmaceutical preparations for
treatment of pinguecula; pharmaceutical preparations for
treatment of chalazion; pharmaceutical preparations for
treatment of uveitis; eye drops for treatment of
keratoconjunctival epithelial disorder; antibacterial eye
drops; antiallergic eye drops; pharmaceutical agents
affecting sensory organs; pharmaceutical preparations for
improving focus-adjustment function declined by
accommodative asthenopia; pharmaceutical preparations for
treatment of accommodative asthenopia; lactose for
pharmaceutical purposes; pharmaceutical preparations;
reagent paper for medical purposes; diagnostic preparations
for medical purposes; oiled paper for medical purposes; drug
delivery agents in the form of edible wafers for wrapping
powdered pharmaceuticals; wrapping wafers for medicine
doses; gauze for dressings; capsules for medicine;
eyepatches for medical purposes; ear bandages; menstruation
bandages; menstruation tampons; sanitary napkins; sanitary
panties; absorbent cotton; adhesive plasters; bandages for
dressings; liquid bandages; breast-nursing pads; cotton
sticks for medical use; diapers for incontinence; diapers;
diaper covers; dietary supplements for humans; nutritional
supplements; dietetic beverages adapted for medical
purposes; dietetic food adapted for medical purposes;
beverages for babies; dietary supplements for animals;
dental cements; mothproofing paper.
96.
DIQUAFOSOL OR SALT THEREOF, AND AQUEOUS OPHTHALMIC COMPOSITION CONTAINING POLYVINYLPYRROLIDONE
The present invention pertains to diquafosol or a salt thereof, and an aqueous ophthalmic composition containing polyvinylpyrrolidone. The present invention further pertains to an aqueous ophthalmic composition for preventing or treating dry eye, the composition containing a 3% (w/v) concentration of sodium diquafosol, polyvinylpyrrolidone having a K value of 90, and silver nitrate, and the composition being characterized by being used so as to be ocularly administered at a dosage of 1 or 2 drops 2 to 4 times daily. The present invention also pertains to an aqueous ophthalmic composition for preventing or treating dry eye, the composition containing a 3% (w/v) concentration of sodium diquafosol, polyvinylpyrrolidone, and silver nitrate, the composition being characterized by being used so as to be ocularly administered at a dosage of one or two drops, two to four times daily, wherein the viscosity is 3 to 30 mPa·s at 25°C.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 31/7084 - Composés ayant deux nucléosides ou nucléotides, p. ex. dinucléotide de la nicotinamide-adénine, dinucléotide de la flavine-adénine
97.
METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL
A method for changing a condition of an eyelid of a hairless animal, a model animal for evaluating a therapeutic or prophylactic effect against an eyelid disease obtained by the method, a method for producing the model animal, a method of screening using the model animal and a substance having a therapeutic or prophylactic effect against an eyelid disease selected by the method of screening, and a therapeutic or prophylactic agent against an eyelid disease containing the substance as an active ingredient.
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A01K 67/027 - Nouvelles races ou races modifiées de vertébrés
A61K 31/7052 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides
98.
OPHTHALMIC COMPOSITION COMPRISING DIQUAFOSOL AND CATIONIC POLYMER
Provided is an ophthalmic composition comprising diquafosol or a salt thereof and a cationic polymer, the cationic polymer being at least one selected from the group consisting of chitosan, a chitosan derivative, a cationic (meth)acrylate copolymer, a cationic silicone polymer, a diallyl quaternary ammonium salt-acrylamide copolymer, cationic hydrolyzed keratin, cationic hydrolyzed silk, cationic hydrolyzed collagen, cationic hydrolyzed casein, cationic hydrolyzed soy protein, a cationic vinylpyrrolidone copolymer, polyvinylpyrrolidone, a dimethyldiacrylammonium chloride homopolymer, an adipic acid-dimethylaminohydroxypropyldiethylenetriamine copolymer, an adipic acid-epoxypropyldiethylenetriamine copolymer and an acrylamide-β-methacryloyloxyethyltrimethylammoniummethyl sulfate copolymer.
A61K 31/675 - Composés du phosphore ayant l'azote comme hétéro-atome d'un cycle, p. ex. phosphate de pyridoxal
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
An ophthalmic aqueous composition comprises levofloxacin, a salt thereof, or a solvate thereof; dexamethasone, an ester thereof, or a salt thereof; and one or at least two isotonic agents. The ophthalmic aqueous composition is substantially free of sodium chloride. This ophthalmic aqueous composition is excellent in drug stability and drug migration and has a clear appearance.
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 31/5383 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 31/496 - Pipérazines non condensées contenant d'autres hétérocycles, p. ex. rifampine, thiothixène ou sparfloxacine
A61K 31/538 - 1,4-Oxazines, p. ex. morpholine condensées en ortho ou en péri avec des systèmes carbocycliques
C07J 5/00 - Stéroïdes normaux contenant du carbone, de l'hydrogène, un halogène ou de l'oxygène, substitués en position 17bèta par une chaîne de deux atomes de carbone, p. ex. prégnane, et substitués en position 21 par seulement une unique liaison carbone-oxygène
The present invention aims to find a pharmaceutical preparation which treats or prevents glaucoma or ocular hypertension and is effective for patients with inadequate efficacies of glaucoma or ocular hypertension therapeutic agents. It has been found that omidenepag, an ester thereof, or a salt thereof has an excellent intraocular pressure lowering efficacy on patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents. Therefore, the omidenepag, the ester thereof, or the salt thereof of the present invention is useful as a pharmaceutical preparation which can treat or prevent glaucoma or ocular hypertension even in patients with inadequate efficacies of other glaucoma or ocular hypertension therapeutic agents.
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
